Single Ascending Doses of BIIB063 in Healthy Volunteers
Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
West Yorkshire
-
Leeds, West Yorkshire, Regno Unito, LD2 9LH
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- All male subjects and all female subjects of childbearing potential must practice at least 1 highly effective method of contraception (i.e., contraceptive measure with a failure rate of <1% per year; estrogen-containing contraceptives are prohibited) during the study and be willing and able to continue contraception for 4 months after being dosed with study treatment. Male subjects must also be willing to refrain from sperm donation for at least 4 months after the last dose of study treatment. Male subjects must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study.
- Must have a body mass index between 18 and 30 kg/m2, inclusive.
- Must be in good health as determined by the Investigator, based on medical history, physical examination, and 12-lead ECG.
Key Exclusion Criteria:
- History of or positive test result at screening for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
- History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
- Personal or family history of cardiovascular disease under the age of 50 years, inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency), or anti-phospholipid Ab syndrome (APS).
- History of meningococcal vaccination or meningococcal meningitis, or history of hypersensitivity to single components of meningococcal vaccines (including MENVEO), any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.
- History of tuberculosis (TB) or positive QuantiFERON®-TB Gold test
- Personal history of thromboembolic events
- Treatment with any prescription or over-the-counter medication within 14 days prior to randomization (excluding vitamins, dietary supplements, herbal preparations, progestin-only birth control, and paracetamol up to 4 g/day for no more than 5 consecutive days).
- Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months
- Current enrollment or a plan to enroll in any other drug, biologic or device clinical study, or treatment with an investigational drug or approved therapy for investigational use within 3 months
- Blood donation (1 unit or more) within 3 months prior to randomization.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: IV Dose 1
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Dose singola
|
|
Sperimentale: IV Dose 2
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Dose singola
|
|
Sperimentale: IV Dose 3
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Dose singola
|
|
Sperimentale: IV Dose 4
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Dose singola
|
|
Sperimentale: IV Dose 5
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Dose singola
|
|
Sperimentale: IV Dose 6
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Dose singola
|
|
Sperimentale: IV Dose 7
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Dose singola
|
|
Sperimentale: SC Dose
Single SC dose or matching placebo
|
Single ascending IV dose
Dose singola
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant laboratory assessment abnormalities
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant Vital sign abnormalities
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant physical examination abnormalities
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for tetanus
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for diphtheria
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for pneumococcus
Lasso di tempo: Up to week 12
|
Up to week 12
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Number of participants with positive serum anti-BIIB063 antibodies
Lasso di tempo: Up to week 12
|
Up to week 12
|
|
Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063
Lasso di tempo: Up to 12 weeks
|
Up to 12 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 234HV101
- 2015-001283-18 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .